The NF1 tumor suppressor protein neurofi bromin is a negative regulator of Ras. Neurofi bromin is dynamically regulated by the proteasome, and its degradation and reexpression are essential for maintaining appropriate levels of Ras-GTP. Like p53, NF1 /neurofi bromin can be inactivated in cancer by both mutations and excessive proteasomal destruction; however, little is known about the mechanisms that underlie this latter process. Here, we show that a Cullin 3 (Cul3)/ kelch repeat and BTB domain-containing 7 complex controls both the regulated proteasomal degradation of neurofi bromin and the pathogenic destabilization of neurofi bromin in glioblastomas. Importantly, RNAi-mediated Cul3 ablation and a dominant-negative Cul3 directly stabilize neurofi bromin, suppress Ras and extracellular signal-regulated kinase, and inhibit proliferation in an NF1 -dependent manner. Moreover, in glioblastomas where neurofi bromin is chronically destabilized, Cul3 inhibition restabilizes the protein and suppresses tumor development. Collectively, these studies show a previously unrecognized role for Cul3 in regulating Ras and provide a molecular framework that can be exploited to develop potential cancer therapies.
INTRODUCTION
The Ras pathway is one of the most commonly deregulated pathways in human cancer (1) (2) (3) . Oncogenic mutations in Ras genes are found in a diverse set of human tumors; however, Ras can also become hyperactivated as a consequence of loss-offunction mutations in genes that encode Ras GTPase-activating proteins (RasGAP), which negatively regulate Ras by catalyzing the hydrolysis of Ras-GTP ( 4-7 ). The NF1 tumor suppressor is the most well-studied RasGAP and is mutated in neurofi bromatosis type I (NF1), a familial cancer syndrome affecting one in 3,500 individuals worldwide ( 8 ) . NF1 has also been shown to be mutated or lost in sporadic glioblastoma (9) (10) (11) , non-small cell lung cancers ( 12 ) , neuroblastoma ( 13, 14 ) , and melanoma (15) (16) (17) , showing a broader role for NF1 in human cancer.
Although tumor suppressors are commonly inactivated by genetic mechanisms, the proteasomal destruction of tumor suppressor proteins such as p53, p27, and PTEN also contributes to their functional inactivation in human cancer (18) (19) (20) (21) . Moreover, in tumor types where p53 is destabilized, strategies aimed at blocking its pathogenic destruction have been an active area of therapeutic development ( 22 ) . Neurofi bromin is also controlled by the ubiquitin-proteasome system, and its expression is dynamically regulated by growth factors in normal settings ( 11 , 23 ) . More recently, we and others have found that NF1 /neurofi bromin expression can be ablated by genetic as well as proteasomal mechanisms in sporadic glioblastomas (9) (10) (11) . However, little is known about the molecular mechanisms that control its regulated or aberrant destruction. Here, we identify the ubiquitin ligase complex that controls neurofi bromin stability in normal and pathogenic settings. Thus, in addition to identifying a new regulator of the Ras pathway, these fi ndings can be used as a foundation for developing new therapeutic approaches to treat cancers such as glioblastomas where neurofi bromin is chronically destabilized. These fi ndings also reveal a new strategy to suppress Ras activation, which may be more broadly exploited to develop therapies for other cancers.
RESULTS

Identifying the Ubiquitin Ligase Complex that Regulates Neurofi bromin Degradation in Response to Growth Factors
We previously reported that a variety of growth factors trigger the acute destruction of neurofi bromin within 5 minutes of exposure, and that protein levels are reelevated 90 minutes thereafter ( 23 ) . Importantly, we showed that (i) this tightly regulated degradation and reexpression of neurofi bromin controls both the amplitude and duration of Ras-extracellular signal-regulated kinase (ERK) signaling in response to growth factors, (ii) neurofi bromin destruction is caused by ubiquitinmediated proteasomal degradation, and (iii) neurofi bromin stabilization prevents aberrant cellular proliferation ( 23 ) . The kinetics of neurofi bromin degradation in response to serum are depicted in Fig. 1A and, as previously observed, its destruction can be blocked by proteasome inhibitors ( Fig. 1B ; refs. 11 , 23 ) . In contrast, other RasGAPs, such as RasGAP 
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To identify the ubiquitin ligase responsible for neurofibromin degradation, we used a short hairpin RNA (shRNA)-based screening approach. We focused on the cullin-RING superfamily of E3 ligases, as these proteins have been shown to play a critical role in cell-cycle regulation and growth control ( 24, 25 ) . Cells were infected with lentiviruses encoding shRNA sequences that recognize each of the mammalian cullin subunits. Depletion of Cullin 3 (Cul3), but not other cullins, blocked the degradation of neurofi bromin in response to serum ( Fig. 1C ) . Notably, Cullin 1, which controls the stability of potential oncogenes and tumor suppressor proteins involved in cell-cycle progression and proliferation, such as cyclin E and p27 ( 26 ) , had no effect on neurofi bromin degradation ( Fig. 1C ) . Two distinct shRNA constructs targeting different regions of Cul3 blocked neurofi bromin degradation, showing that this phenotype is not an off-target effect ( Fig. 1D ) .
We have previously shown that growth factors trigger neurofi bromin destabilization by activating protein kinase C (PKC), which provides a signal that is both necessary and suffi cient for neurofi bromin destruction ( 11 ) . To determine whether Cul3 mediates PKC-regulated neurofi bromin degradation, cells were treated with the PKC activator PMA (phorbol-12-myristate-13-acetate). Although neurofi bromin was degraded in response to PKC activation in control cells, PMA-induced degradation was blocked in Cul3-depleted cells ( Fig. 1E ) . These results indicate that Cul3 mediates the PKCdriven destabilization of neurofi bromin.
Endogenous Cul3 Interacts with Neurofi bromin and Controls Neurofi bromin Ubiquitination and Degradation
To determine whether Cul3 directly regulates neurofi bromin stability, cells were pretreated with proteasome inhibitors, serum-starved NIH3T3 fi broblasts stimulated with 10% serum for the times shown. RasGAP p120 (p120) is not degraded under these conditions and is shown as a loading control. B, serum-starved MEFs were treated with a combination of proteasome inhibitors (1 μmol/L bortezomib, 10 mmol/L MG132) or vehicle (dimethyl sulfoxide) for 2 hours and then stimulated with 10% serum for the times indicated. Immunoblots of neurofi bromin and RasGAP p120 are shown. C, NIH3T3 fi broblasts were infected with a lentiviral control or a lentivirus containing an shRNA sequence directed against specifi c mammalian cullin genes as noted. Knockdown of cullins was confi rmed by immunoblotting (IB). Neurofi bromin and RasGAP p120 immunoblots of serum-starved cells stimulated with 10% serum for the times indicated are shown. D, immunoblot of neurofi bromin degradation in NIH3T3 fi broblasts expressing a control shRNA vector or distinct shRNA constructs targeting different regions of the Cul3 transcript. Cul3 depletion was confi rmed by immunoblot, and RasGAP p120 levels are shown as a loading control. E, immunoblot of neurofi bromin degradation in control or sh Cul3 -expressing NIH3T3 fi broblasts following PKC activation (10 nmol/L PMA) for 5 minutes. Cul3 depletion and a RasGAP p120 loading control are also shown. MEF, mouse embryonic fi broblasts; shRNA, short hairpin RNA; PKC, protein kinase C; PMA, phorbol-12-myristate-13-acetate. 
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and neurofi bromin or Cul3 was immunoprecipitated from serum-stimulated cells. Importantly, endogenous neurofi bromin and endogenous Cul3 coprecipitate under the precise conditions in which neurofi bromin is normally degraded ( Fig. 2A ) . To confi rm a functional role for Cul3 in this complex, we used a dominant-negative fragment of Cul3 (DN-Cul3). When expressed as a truncated fragment, the N-terminal half of Cul3 functions as a dominant-negative protein because it can bind Cul3 targets but is unable to recruit the E2 ubiquitin-conjugating enzyme ( 27, 28 ) . As such, Cul3 substrates directly associate with this fragment but cannot become ubiquitinated or degraded. Similar to endogenous Cul3, DN-Cul3 also formed a stable complex with endogenous neurofi bromin in vivo ( Fig. 2B ) . Neurofi bromin did not coprecipitate with a DN-Cul4A fragment, further highlighting the specifi city of this interaction. Similar to the effects of Cul3 shRNAs, DN-Cul3 substantially blocked neurofi bromin degradation ( Fig. 2C ) .
Proteins that are targeted to the proteasome for degradation are fi rst covalently modifi ed with polyubiquitin chains, Immunoblots (IB) of neurofi bromin or Cul3 immunocomplexes and whole-cell lysates (WCL) are shown. B, neurofi bromin was immunoprecipitated from NIH3T3 fi broblasts expressing dominant-negative (DN) versions of Cul3 and Cul4A. Expression of DN cullins in total cell lysates was confi rmed with an anti-HA antibody and equal loading was confi rmed by a RasGAP p120 immunoblot. Immunoblots using a neurofi bromin antibody and an HA antibody confi rm the specifi c association of DN-Cul3 with neurofi bromin. C, immunoblot assessing the effect of lentivirally expressed HA-tagged DN-Cul3 or a lentiviral control vector on neurofi bromin stability in serum-stimulated NIH-3T3 fi broblasts. Expression of DN-Cul3 was detected using an anti-HA antibody. RasGAP p120 levels are shown as a loading control. D, serum-starved NIH3T3 fi broblasts expressing a control lentiviral vector or a Cul3 -specifi c shRNA were treated with proteasome inhibitors (1 μmol/L bortezomib, 10 mmol/L MG132) for 2 hours, and stimulated with 10% serum for 5 minutes. Total cell lysates were isolated in buffer containing 2 nmol/L N-ethyl-maleimide to preserve polyubiquitin chains. Neurofi bromin or control immunoprecipitations are shown. Both ubiquitin and neurofi bromin blots denote a decrease in high-mobility ubiquitinated neurofi bromin (brackets) in cells depleted of Cul3. An arrow points to unmodifi ed neurofi bromin. Cul3 levels and a RasGAP p120 loading control are also shown. E, Western blot depicting the expression of ectopic HA-tagged Cul3 used for in vitro ubiquitination reactions (top). Neurofi bromin blot showing an increase in ubiquitinated neurofi bromin catalyzed by endogenous Cul3 complexes immunoprecipitated from stimulated cells (bottom). These in vitro reactions included recombinant human E1, E2 (UBCH5a), ubiquitin, and an ATP-regenerating system. An arrow points to unmodifi ed neurofi bromin and a bracket indicates the location of polyubiquitinated neurofi bromin. IgG, immunoglobulin G. 
resulting in the accumulation of higher-mobility species of the target protein ( 29 ) . To confi rm that Cul3 indeed controls ubiquitination, we examined the ubiquitination state of neurofi bromin in wild-type cells or in cells in which Cul3 expression was suppressed by RNA interference (RNAi). Consistent with previous reports, neurofi bromin is ubiquitinated in serum-treated cells exposed to proteasome inhibitors, which can be visualized as a high-mobility smear that can be detected by both NF1 and ubiquitin antibodies ( Fig. 2D ; refs.  11 , 23 ) . Importantly, Cul3 -specifi c shRNA sequences dramatically suppressed neurofi bromin ubiquitination ( Fig. 2D ) . To determine whether Cul3 was directly mediating this ubiquitination, we generated a Cul3 expression construct and confi rmed that immunoprecipitated, recombinant Cul3 could ubiquitinate Nrf2, a well-established Cul3 substrate ( Fig. 2E and Supplementary Fig. S1 ). This immunopurifi ed, recombinant Cul3 also ubiquitinated neurofi bromin in a reconstituted in vitro ubiquitination assay ( Fig. 2E ) . It should be noted that although ubiquitinated neurofi bromin extracted from cells is manifested as a high-mobility smear on immunoblots, we have consistently found that neurofi bromin ubiquitinated in vitro migrates as a more concentrated highmobility species, with less of a smeared pattern ( 11 , 23 ) . This is likely due to the large size of ubiquitinated neurofi bromin (>250 kDa), which becomes maximally ubiquitinated in vitro , in addition to the activity of deubiquitinating enzymes in vivo . Together, the endogenous coprecipitation data, RNAi and dominant-negative experiments, as well as these in vitro and in vivo ubiquitination studies, show that Cul3 directly controls the dynamic ubiquitination and degradation of neurofi bromin.
Cul3 Loss Suppresses Ras/ERK Signaling
Because neurofi bromin is a RasGAP, the effects of Cul3 suppression on the Ras/ERK pathway were examined. In response to serum and growth factors, ERK and Ras were maximally activated within 5 minutes ( Fig. 3A and B ) . However Cul3 -specifi c shRNAs suppressed ERK activity by nearly 60% ( Fig. 3A ) . DN-Cul3 exhibited a similar suppressive effect (60%) on Ras-GTP levels directly ( Fig. 3B ) and similarly suppressed ERK activity ( Supplementary Fig. S2A ). We next evaluated the relative contribution of neurofi bromin stabilization in mediating this suppressive effect on Ras signaling. Cul3 shRNA constructs suppressed ERK activation by 87% ( Fig. 3C ), underscoring the potent effects of Cul3 suppression on this pathway. RNAi-mediated neurofi bromin suppression had no effect on ERK activity on its own in this setting ( Fig. 3C ). However, Nf1 ablation substantially rescued the defects in ERK signaling, increasing ERK activation sixfold and restoring it to 66% of maximal levels ( Fig. 3C ). Taken together, these data show that Cul3-mediated neurofi bromin degradation plays an essential role in regulating Ras and ERK and that Cul3 suppression potently inhibits this pathway. Surprisingly, however, although depletion of neurofi bromin substantially restored ERK activation in Cul3-defi cient cells, a complete rescue was not observed, suggesting that Cul3 may have additional targets that impact Ras activation. Thus, in addition to revealing a previously unrecognized role for Cul3 in regulating Ras, the observation that Cul3 may affect this pathway through neurofi bromin and possibly an additional target protein strengthens the potential use of Cul3 inhibition in suppressing the Ras pathway.
Growth Suppression Conferred by Dominant-Negative Cul3 Is Dependent on NF1
The amplitude and duration of Ras/ERK activation have been shown to play an important role in restricting or permitting cellular proliferation ( 30 ) . We therefore evaluated the effects of Cul3 suppression on cellular proliferation. shRNA-mediated depletion of Cul3 in mouse embryonic fi broblasts (MEF) led to acute cell death (not shown), indicating that a minimal threshold of Cul3 activity is required for the viability of these cells, as has been previously reported ( 31 ) . However, expression of dominant-negative Cul3 (DNCul3) was tolerated. To control for the effects of DN-Cul3 in these cells, we also evaluated a mutant form of DN-Cul3 that cannot bind its substrates (L52AE55A), hereafter referred to as DN-Cul3mut ( 32 ) . We validated these DN-Cul3 constructs by showing that expression of DN-Cul3 stabilized the transcription factor Nrf2, a well-established target of Cul3, whereas expression of DN-Cul3mut had no effect (Supplementary Fig. S2B ). Importantly, DN-Cul3, but not DNCul3mut, inhibited proliferation and ultimately caused a growth arrest in wild-type MEFs ( Fig. 3D ). In contrast, Nf1 −/− MEFs, which lack neurofi bromin, were unaffected by the expression of DN-Cul3 and proliferated indistinguishably from Nf1 −/− MEFs expressing DN-Cul3mut ( Fig. 3D ). Notably, DN-Cul3, but not DN-Cul3mut, led to a decrease in activated ERK in wild-type MEFs, whereas ERK activation was not hampered by DN-Cul3 in Nf1 −/− MEFs ( Supplementary Fig. S2A ). These results show that the growthinhibitory effects of Cul3 suppression are dependent on neurofi bromin.
Cul3 Regulates Neurofi bromin Destabilization in Glioblastomas
We and others have shown that one NF1 allele is mutated or lost in 15% to 23% of sporadic glioblastomas. However biallelic inactivation occurs in only 3% of tumors and cell lines ( 9-11 , 33 ) . Nevertheless, neurofi bromin protein expression is suppressed or absent in a much higher fraction of tumors ( 11 ) . We have shown this suppression is caused by excessive ubiquitin-mediated proteasomal degradation and that neurofi bromin destabilization plays an active role in driving tumor pathogenesis ( 11 ) . To determine whether Cul3 was responsible for the destabilization of neurofi bromin in glioblastomas, we expressed DN-Cul3 in three cell lines where neurofi bromin has been shown to be destabilized: U87MG, Gli36, and SF539. In all cases, DN-Cul3 expression resulted in an increase in the expression of neurofi bromin protein ( Fig. 4A ) . Cul3 shRNA sequences similarly stabilized neurofibromin in these cells (Supplementary Fig. S3 ). Importantly, DN-Cul3 also coprecipitated with endogenous neurofi bromin ( Fig. 4B ) , suggesting that these effects were direct, consistent with the analysis shown in Fig. 2 from serum-stimulated NIH3T3 fi broblasts expressing a lentiviral control shRNA or a Cul3 -specifi c shRNA (left). Right, quantifi cation of relative levels of activated ERK in shControl or shCul3-expressing cells using ImageJ software (right). B, immunoblot of a Ras-GTP pulldown assay to assess activation of Ras in MEFs expressing a lentiviral control vector or dominant-negative Cul3 (DN-Cul3) following treatment with LPA for the times indicated (left). Right, relative levels of Ras activation quantifi ed using ImageJ software and depicted as a percentage of maximal Ras activation compared with vector control-expressing cells. C, immunoblot of phosphorylated ERK, Cul3, neurofi bromin, and RasGAP p120 from NIH3T3 fi broblasts expressing lentiviral control vectors or Cul3 and NF1-specifi c shRNAs individually or in tandem (left). Right, quantifi cation of relative activated ERK levels using ImageJ software, denoting that the attenuation in ERK activation due to Cul3 defi ciency is rescued in part by the ablation of Nf1 expression. D, relative proliferation curves of NF1 wild-type ( Nf1 
RESEARCH ARTICLE
adaptors contain a BTB protein-protein interaction domain (for Bric-a-brac, Tramtrack, Broad complex; refs. 27 , 32 , 34, 35 ) . BTB domain proteins bind to Cul3 through the BTB domain and recruit substrates through diverse protein-protein interaction motifs ( 36 ) . To further dissect the mechanism by which Cul3 regulates neurofi bromin stability, we conducted a proteomic/mass spectrometry-based screen to identify the neurofi bromin-associated BTB adaptor protein. Similar strategies have been used to identify components of E3 ubiquitin ligase complexes for a variety of substrates (37) (38) (39) . Specifi cally, mass spectrometry was conducted on endogenous neurofi bromin immunoprecipitates, generated from serum-stimulated cells in the presence of proteasome inhibitors. Using this approach, we detected the BTB domain-containing protein kelch repeat and BTB domaincontaining 7 (KBTBD7) in the neurofi bromin immunoprecipitates. To validate this interaction, we expressed an epitope-tagged KBTBD7 construct, as reliable antibodies for KBTBD7 are not presently available. Importantly, HA-KBTBD7 could be readily detected in a complex with endogenous neurofi bromin ( Fig. 4C ) . Although KBTBD7 contains a BTB domain, its ability to interact with Cul3 has not been previously evaluated. Importantly, endogenous Cul3 coprecipitated with KLHL21, an established Cul3-binding BTB protein ( 40 ) , as well as KBTBD7 ( Fig. 4D ) . Moreover, shRNA-mediated depletion of Kbtbd7 blocked the serumstimulated degradation of neurofi bromin in NIH3T3 cells ( Fig. 4E ) , mirroring the block in neurofi bromin degradation caused by Cul3 depletion ( Figs. 1 and 2 ) . Finally, RNAi-mediated KBTBD7 depletion caused an increase in neurofi bromin levels in glioblastoma cell lines in which neurofi bromin is normally destabilized ( Fig. 4F and G ) . Together, these fi ndings show that Cul3 uses KBTBD7 as the adaptor protein to regulate neurofi bromin stability.
DN-Cul3 Suppresses Transformation and Tumor Growth through Its Effects on Neurofi bromin
The observation that neurofi bromin was stabilized by Cul3 shRNAs and DN-Cul3 raised the intriguing possibility that Cul3 inhibition might also suppress the transformed properties of these cancer cells. To ascertain the biologic consequences of Cul3 suppression in glioblastomas, we compared the effects of the DN-Cul3 in glioblastoma cells in which neurofi bromin was destabilized by the proteasome, as compared with cells that were confi rmed to be genetically NF1 -defi cient ( 11 ) . Expression of DN-Cul3 significantly reduced the ability of NF1 wild-type/neurofi bromindestabilized glioblastoma cells to form colonies in soft agar, as compared with cells that expressed equivalent levels of the control DN-Cul3mut, which had no effect in preventing colony growth ( Fig. 5A and B ) . In contrast, DN-Cul3 had no effect on the ability of NF1 -null cells to form colonies ( Fig. 5A and B ) .
Finally, we investigated whether DN-Cul3 activity could affect the ability of glioblastoma cells to form xenograft tumors in vivo . Although U87 cells readily formed tumors in the fl anks of immunocompromised mice, DN-Cul3 potently suppressed tumor development ( Fig. 5C ; P = 0.00044). In contrast, expression of DN-Cul3 did not prevent tumor growth in mice injected with NF1 -null LN319 cells, which are genetically NF1 -defi cient. Because DN-Cul3 likely affects other targets, we directly evaluated the contribution of neurofi bromin stabilization in tumor suppression. To examine this in an isogenic setting, we used U87shp53 cells, which are able to tolerate complete NF1 ablation ( 11 ) . DN-Cul3, but not control DN-Cul3mut, similarly inhibited tumor growth when expressed in these cells. However, RNAi-mediated NF1 suppression restored tumorigenicity ( Fig. 5D-F ) , indicating that the tumor-suppressive effects of DN-Cul3 were dependent on NF1. Collectively, these data show that Cul3 suppression can potently inhibit the tumorigenic properties of glioblastomas in which neurofi bromin has been inactivated by the proteasome, thus revealing a mechanism-based vulnerability that can be used to develop new potential therapies. Importantly, this vulnerability may extend beyond glioblastomas and may ultimately be harnessed as a means of suppressing Ras signaling in other cancers. A model describing the pathway identifi ed here is shown in Fig. 6 .
DISCUSSION
The Ras pathway plays an essential role in transducing signals from activated growth factor receptors and regulates a wide variety of biologic responses ( 30 ). The proper intensity of Ras/ERK signaling has been shown to be essential for dictating specifi c cellular responses and can determine whether a cell proliferates, arrests, differentiates, survives, or dies ( 30 , 41 ) . However, there is still little known about the precise molecular events that regulate the timing, duration, and intensity of Ras signaling that control these diverse biologic behaviors. Here, we report that Cul3 and the BTB adaptor protein KBTBD7 regulate the ubiquitination and rapid degradation of neurofi bromin in response to growth factors. Although we cannot rule out the involvement of additional ligases in some settings, in this report we show that Cul3 is essential for full activation of the Ras/ERK pathway. Moreover, Cul3 suppression potently inhibits Ras/ERK activation and cellular proliferation through its effects on neurofi bromin. Thus, these studies reveal a previously unrecognized regulatory component of the Ras signal transduction pathway and provide fundamental insight into how Ras activity is so exquisitely regulated.
Notably, the excessive destabilization of neurofi bromin has also been shown to underlie the pathogenesis of glioblastomas ( 11 ) . Here, we show that Cul3 and KBTBD7 also mediate this instability. Moreover, Cul3 suppression potently inhibits tumorigenicity by stabilizing neurofi bromin. We have previously reported that PKC activation triggers neurofi bromin degradation in response to growth factors and that excessive PKC activity causes chronic destabilization in a subset of glioblastomas ( 11 , 23 ) . The molecular events that drive this destruction are currently unknown; however, the insight provided in this study will serve as the foundation for future investigations. Importantly, an oncogenic role for Cul3 or KBTBD7 has not previously been described in the pathogenesis of human cancer. Moreover, the involvement of Cul3 in regulating neurofi bromin and Ras may be exploited to suppress tumor development. For example, based on these studies, a Cul3 or a general cullin inhibitor would be expected to inhibit tumors in which neurofi bromin is destabilized (e.g., glioblastomas). Notably, a small-molecule inhibitor that targets NEDD8, a critical regulatory component of the cullin-RING ligases, has already been developed (MLN4924; ref. 42 ) . MNL4924 has been shown to trigger cell death in a variety of cancer cell lines, exhibits signifi cant antitumor activity in xenograft assays, and is presently being evaluated in several phase I clinical trials for solid tumors and hematologic malignancies ( 42, 43 ) . More recently, cell-based screens identifying inhibitors of individual cullin-RING ligases have been reported (44) (45) (46) , describing the fi rst attempts at drug discovery for this class of ubiquitin ligases. Finally, the insight that p53 is degraded by the ubiquitin-proteasome system has inspired the development of numerous small-molecule inhibitors specifi cally aimed at blocking its destruction, which are now being extensively evaluated in the clinic ( 22 , 47 ) . Thus, the observations presented here should provide the molecular framework and rationale to evaluate and develop agents aimed at blocking neurofi bromin destruction and Ras activation, which may impact therapeutic development in glioblastoma, and possibly other cancers which more generally rely on receptor tyrosine kinase/Ras signaling networks.
METHODS
Cell Culture
NIH3T3 fi broblasts were cultured in Dulbecco's Modifi ed Eagle Medium (DMEM) supplemented with calf serum. Primary MEFs and 293T cells were cultured in DMEM supplemented with fetal calf serum (FCS) and L -glutamine. For serum starvation involving NIH3T3 fi broblasts, cells were trypsinized, neutralized with 0.5 mg/mL soybean trypsin inhibitor in DMEM, washed, and plated as indicated below in serum-free media. MEFs were made quiescent as previously described ( 48 ) by fi rst growing to confl uency over 72 hours, then changing media to 0.1% FCS for 72 additional hours and washed, resuspended, and plated in serum-free media for 18 hours before stimulation. U87, Gli36, SF539, and LN319 glioblastoma cells were cultured in DMEM supplemented with 10% FCS and L -glutamine. All non-MEF cell lines were obtained from the American Type Culture Collection (ATCC). No additional authentication was conducted by the authors. 
Degradation Time Courses and Proteasome Inhibition
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were treated with 10 nmol/L PMA. Quiescent MEFs were plated at a density of 5 × 10 5 cells/10 cm culture dish for 18 hours and stimulated with 10% FCS or 6 μmol/L lysophosphatidic acid (LPA) for the times indicated. Cells were lysed at specifi ed time points with 1% SDS boiling lysis buffer and clarifi ed. For experiments that required proteasome inhibition as indicated in the text, cells were pretreated with 1 μmol/L bortezomib (LC laboratories) and 10 μmol/L MG 132 (Boston Biochem) or vehicle (dimethyl sulfoxide) for 2 hours before stimulation with serum or LPA.
Immunoblotting
Clarifi ed cell lysates were normalized for protein concentration, separated by SDS-PAGE, and transferred to Immobilon-P polyvinylidene difl uoride membrane for immunoblotting with the following antibodies: neurofi bromin antibodies: UP69: a polyclonal antibody raised against a keyhole limpet hemocyanin-conjugated peptide, RNSIKKIV, 1:5,000; or NF1-A300-140A (Bethyl), 1:1,000; p120RasGAP (Transduction Laboratories), 1:2,000; HA (for epitope-tagged contructs; 12CA5, Roche), 1:1,000; Cul3 (BD-Transduction), 1:1,000; pan-Ras (Millipore), 1:20,000; Nrf2 (C-20, Santa Cruz), 1:1,000; phosphorylated ERK (Transduction Laboratories), 1:3,000; ERK (Transduction Laboratories), 1:3,000; ubiquitin (DAKO), 1:1,000.
Interactions between Neurofi bromin and Cul3
To detect interactions between endogenous Cul3 and neurofi bromin, serum-starved NIH3T3 cells were treated with proteasome inhibitors and stimulated with serum, as described above. At the time of serum stimulation, the chemical cross-linker DSP [dithiobis(succinimidylpr opionate)] (Thermo Scientifi c) was added to a fi nal concentration of 1 mmol/L for 20 minutes, and the reaction quenched with 100 mmol/L Tris for 10 minutes, before lysis in ice-cold immunoprecipitation (IP) buffer (0.3% CHAPS, 10 mmol/L HEPES pH 7.5, 120 nmol/L NaCl, 1 mmol/L EDTA, 10 mmol/L sodium pyrophosphate, 50 mmol/L sodium fl uoride) supplemented with protease and phosphatase inhibitors (Roche). Lysates were incubated for 15 minutes on ice, clarifi ed, combined, and split into equivalent samples for parallel immunoprecipitations of neurofi bromin, Cul3, or a control reaction with 2 μg each of neurofi bromin-D antibody (Santa Cruz), Cul3 antibody (H-293; Santa Cruz), or normal rabbit immunoglobulin G (IgG) (Cell Signaling), rotating overnight at 4°C. Immunoprecipitations were immobilized on Protein A beads, rotating for 1 hour at 4°C, and washed three times with IP buffer before denaturation and separation by SDS-PAGE. Western blots were probed with antibodies as described above, using conformationspecifi c secondary antibodies (Rockland). To detect interactions between DN-Cul3 and neurofi bromin, cells were transduced with DN-Cul3 (see below) or control vectors as described in the text. Neurofi bromin was immmunoprecipitated from cells using IP buffer supplemented with protease and phosphatase inhibitors only (Roche). Samples were immobilized on Protein A beads, washed three times with IP buffer, and separated by SDS-PAGE before Western blot analysis.
Detection of Ubiquitinated NF1 In Vivo
NIH3T3 cells were stably transduced with a pLKO control vector or pLKO containing a Cul3 shRNA and plated in serum-free DMEM at a density of 5 × 10 5 cells/10 cm culture dish. After 18 hours, cells were treated with a combination of 10 μmol/L MG132 and 1 μmol/L bortezomib for 2 hours, then stimulated for 5 minutes with 10% calf serum before lysing cells. To enrich for ubiquitinated neurofibromin, three 10 cm dishes for each condition were washed and lysed in ice-cold radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors (Roche), supplemented with 2 mmol/L N-ethyl-maleimide (Sigma), which inactivates deubiquitinase enzymes. Lysates were clarifi ed and precleared with Protein A beads, and neurofi bromin was immunoprecipitated with 2 μg neurofi bromin-D antibody (Santa Cruz), and an equivalent control sample with rabbit IgG (Cell Signaling), rotating overnight at 4°C. Immunocomplexes were immobilized on Protein A beads, rotating for 1 hour at 4°C, then washed three times with wash buffer before denaturation and separation by SDS-PAGE. Western blots were probed with ubiquitin antibody (DAKO), then stripped and reprobed with neurofi bromin antibody (Bethyl), using conformation-specifi c secondary antibodies (Rockland).
In Vitro Ubiquitination
Neurofi bromin immunoprecipitated from cycling NIH3T3 cells was used as a ubiquitination substrate (ATCC). Specifi cally, two 15 cm dishes were washed three times with PBS and lysed with ice-cold IP buffer (0.3% CHAPS, 10 mmol/L HEPES pH 7.5, 120 nmol/L NaCl, 1 mmol/L EDTA, 10 mmol/L sodium pyrophosphate, 50 mmol/L sodium fl uoride) supplemented with protease and phosphatase inhibitors (Roche). Lysates were incubated for 15 minutes on ice, clarifi ed, combined and split into equal amounts for parallel immunoprecipitations, each with 2 μg neurofi bromin-D antibody (Santa Cruz), rotating overnight at 4°C. Immunoprecipitations were immobilized on Protein A beads, rotating for 1 hour at 4°C, then washed three times with IP buffer followed by three times with ubiquitination wash buffer (50 mmol/L Tris-HCl pH 7.5, 5 mmol/L MgCl 2 ). To assess NF1 ubiquitination catalyzed by Cul3 directly, exogenous HA-tagged Cul3 was expressed in NIH3T3 cells. Cells were stimulated with serum for 2 minutes, and Cul3 was immunoprecipitated in ice-cold IP buffer for 2 hours and immobilized on protein A beads, washed three times with IP buffer and ubiquitination wash buffer (50 mmol/L Tris-HCl pH 7.5 and 5 mmol/L MgCl 2 ) before in vitro ubiquitination reactions. Ubiquitination reactions were assembled containing the following and mixed with NF1-IP-beads: 50 mmol/L Tris-HCl pH.7.5, 5 mmol/L MgCl 2 , 2 mmol/L ATP (Sigma), 10 mmol/L phosphocreatine (Sigma), 3.5 U/mL creatine phosphokinase (Sigma), 1 μmol/L ubiquitin aldehyde (Boston Biochem), 5 μg ubiquitin (Boston Biochem), 220 ng human E1 (Boston Biochem), 500 ng E2 (UbcH5a) (Boston Biochem), and HA-Cul3 IP or control beads from an IgG immunoprecipitation as shown. Reactions were incubated at 37°C for 90 minutes and stopped by boiling in Laemmli buffer for 5 minutes. Western blots were immunoblotted with neurofi bromin antibody (Bethyl). For ubiquitination reactions using Nrf2 as a substrate, GFP-Nrf2 was expressed in 293T cells and immunopurifi ed with a GFP antibody (Invitrogen). Ubiquitination reactions were set up as described above.
Generation of Constructs
DN-CUL3 (amino acids 1-418) and DN-CUL4A (amino acids 1-439) were cloned by PCR amplifi cation including an N-terminal HA epitope. All fragments were cloned into pENTR-D TOPO (Invitrogen) according to the manufacturer's instructions to generate pENTR-D clones containing HA-tagged DN-cullins. Mutant DN-Cul3 (L52AE55A) was generated using a site-directed mutagenesis kit (Clontech). Entry clones were subcloned into pLenti TO-puro destination vector ( 49 ) via Gateway-mediated LR recombination (Invitrogen) to generate lentiviral expression vectors. Clones expressing full-length cDNAs of KBTBD7, KLHL21, LacZ, and Nrf2 in the pDONR223 vector were obtained from the Human Orfeome collection (Dana-Farber Cancer Center, Boston, MA) and subcloned into the lentiviral expression vector pHAGE-C-HA-FLAG (W. Harper, Harvard Medical School, Boston, MA) by Gateway recombination using LR-clonase II (Invitrogen) according to the manufacturer's instructions. Nrf2 was cloned into pHAGE N-GFP-blast expression vector (W. Harper). All fi nal sequences were verifi ed.
Retroviral and Lentiviral Infections
The lentiviral vector pLKO containing the following shRNAs was used: sh Cul3 (CCGGCGTGTTATAGACCACTC), sh Cul1 
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(CCGCACTTAAATCAATACATT), sh Cul2 (GCATCCAAG-TTCAT ATACTAA), sh Cul4B (GCTGTCTGATTTGCAAATTTA), sh Cul5 (CGAGAGTCCTATGTTAATCTT), and sh KBTBD7 (GAATTAAAG GACAGGCCAT). The retroviral vector pSUPER-Retro containing the following shRNAs was used: Cul3 #1 (CCTCCAAGAATCCT TCAATAA), Cul3 #2 (GCGAATAATGAAGTCTAGGAA) Cul3 #3 (CGAGATCAAG-TTGTACGGTAT), and Cul3 #4 (CCAGGGCT TATTGGATCTAAA). Lentiviruses were produced by transfection of the 293T packaging cell line with the appropriate lentiviral expression vector, pLKO for shRNAs (TRC, Broad Institute) and pLentiTO or pHAGE-C-HA-FLAG for expression constructs, along with Δ8.2 (encoding gag, pol, and rev) and VSVG using Fugene 6 (Roche). Retroviruses were produced by transfection of the 293T packaging cell line with the appropriate retroviral expression vector and a vector encoding a replication-defective helper virus, pCL-Eco (Imgenex), using Fugene 6 (Roche). Virus-containing media was used to transduce target cells. Puromycin (2 μg/mL) was used to select stably transduced cell lines.
Identifi cation of Neurofi bromin-Interacting BTB Proteins
Briefl y, a hundred 15 cm plates of serum-deprived T98G glioblastoma cells were pretreated with proteasome inhibitors for 2 hours and restimulated with FCS. Cells were rinsed three times with PBS and lysed in ice-cold 0.3% CHAPS buffer (0.3% CHAPS, 10 mmol/L HEPES pH 7.5, 120 nmol/L NaCl, 1 mmol/L EDTA, 10 mmol/L sodium pyrophosphate, 50 mmol/L sodium fl uoride) supplemented with protease and phosphatase inhibitors (Roche). Lysates were incubated for 15 minutes on ice, clarifi ed, precleared two times with agarose beads and two times with protein A beads for 1 hour each time, and split into equal amounts for parallel immunoprecipitations with 50 μg of neurofi bromin antibodies (sc-67 or sc-68; Santa Cruz), rotating overnight at 4°C. Immunoprecipitations were immobilized on 150 μL Protein A beads, rotating for 2 hours at 4°C, and washed fi ve times with IP buffer. Samples were separated by SDS-PAGE on 4%-12% gradient mini gels, and proteins were visualized with Coomassie Safely Blue stain (Invitrogen). The experimental lines were excised into small fragments, rinsed in 10% acetonitrile, and submitted for mass spectrometry analysis at the Beth Israel Deaconess Medical Center Mass Spectrometry Core facility.
Quantitative PCR
To detect shRNA-mediated knockdown of Kbtbd7 and KBTBD7 in mouse and human cell experiments, respectively, total RNA was extracted from cells using TRIzol (Invitrogen), and cDNA was synthesized using the qScript cDNA Synthesis Kit (Quanta), following the manufacturer's instructions. Quantitative PCR was conducted using PerfeCTa Sybr Green Mix (Quanta) following the manufacturer's instructions. Expression levels of Kbtbd7 were normalized against Gapdh expression, and KBTBD7 expression was normalized to HPRT1 expression. The following primers were used: Kbtbd7_F (5′-aagag cactacctggga-3′), Kbtbd7_R (5′-cttggcaaccactgacttgt-3′), Gapdh_F (5′-actccactcacggcaaattc-3′), Gapdh_R (5-tctccatggtggtgaagaca-3′), KBTBD7_F (5′-cagtccgctcactctctatgt-3′), KBTBD7_R (5′-agacgccttc gaccatcac-3′), HPRT1_F (5′-gccggctccgttatgg-3′), HPRT1_R (5′-aacct ggttcatcatcactaatca-3′).
Ras Activation Analysis
Primary MEFs were serum-starved by culturing to confl uency for 4 days in DMEM supplemented with 10% FCS, then changing media to 0.1% FCS for 3 additional days. Cells were then resuspended, washed, and plated in serum-free DMEM overnight. Cells were stimulated with 6 μmol/L LPA for the times indicated. Ras-GTP levels were detected using a Ras activation assay, following the manufacturer's instructions (Upstate). Ras activation was quantifi ed by using DNA j software to assess the amount of Ras that was pulled down by GSTRas-binding domain fusion protein divided by total levels of Ras in the lysates. Values at 5 and 15 minutes were then divided by values observed in unstimulated control cells to establish relative levels of Ras activation.
Proliferation Studies
Quiescent MEFs were split to a density of 150,000 cells per well of a six-well dish in triplicate and then stimulated with serum. At each indicated time, cells were trypsinized and counted. Fold increase in cell number ratios was calculated by dividing the average cell number of three plates in serum at the indicated time points by the average cell number of three plates in serum-free medium after 18 hours.
Colony Growth in Soft Agar
Soft agar assays were conducted as previously described ( 50 ) .
Xenograft Tumor Studies
All animal procedures were approved by the Center for Animal and Comparative Medicine at the Harvard Medical School in accordance with the NIH Guild for the Care and Use of Laboratory Animals and the Animal Welfare Act. Subcutaneous implantations were carried out in 6-week-old athymic female nude mice (Charles River) by injecting 10 6 cells in 100 μL of PBS (six or eight injections per condition as described in the text). Two weeks after injection (day 0), the width and length of the tumor were measured twice weekly by caliper and the volume was calculated with the following formula: volume = (length × width 2 )π/6. Tumors were monitored for 5 months.
Statistical Analyses
If data were normally distributed, statistical analysis was done by Student t test. Otherwise, we used the Mann-Whitney U test. Specifi c tests are noted in the text and fi gure legends. All numerical data, including error bars, represent the mean ± SD of experiments carried out in triplicate. 
